Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

G. Mantovani, D. Treppiedi, E. Giardino, R. Catalano, F. Mangili, P. Vercesi, M. Arosio, A. Spada, E. Peverelli

Research output: Contribution to journalReview article

Abstract

Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

Original languageEnglish
Pages (from-to)R95-R108
JournalEndocrine-Related Cancer
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Microfilament Proteins
Filamins
Pituitary Neoplasms
Cytoskeleton
Somatostatin Receptors
Actin Depolymerizing Factors
Dopamine Agents
Dopamine Agonists
Dopamine Receptors
Neurosurgery
Somatostatin
Drug Resistance
Actins
Dopamine
Pharmacology
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • Cofilin
  • Dopamine receptor type 2
  • Filamin A
  • Pituitary tumors
  • Somatostatin receptor 2

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. / Mantovani, G.; Treppiedi, D.; Giardino, E.; Catalano, R.; Mangili, F.; Vercesi, P.; Arosio, M.; Spada, A.; Peverelli, E.

In: Endocrine-Related Cancer, Vol. 26, No. 2, 01.02.2019, p. R95-R108.

Research output: Contribution to journalReview article

Mantovani, G. ; Treppiedi, D. ; Giardino, E. ; Catalano, R. ; Mangili, F. ; Vercesi, P. ; Arosio, M. ; Spada, A. ; Peverelli, E. / Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. In: Endocrine-Related Cancer. 2019 ; Vol. 26, No. 2. pp. R95-R108.
@article{cd2c10871a0a46509cd46983de6a4786,
title = "Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors",
abstract = "Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.",
keywords = "Cofilin, Dopamine receptor type 2, Filamin A, Pituitary tumors, Somatostatin receptor 2",
author = "G. Mantovani and D. Treppiedi and E. Giardino and R. Catalano and F. Mangili and P. Vercesi and M. Arosio and A. Spada and E. Peverelli",
year = "2019",
month = "2",
day = "1",
doi = "10.1530/ERC-18-0442",
language = "English",
volume = "26",
pages = "R95--R108",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

AU - Mantovani, G.

AU - Treppiedi, D.

AU - Giardino, E.

AU - Catalano, R.

AU - Mangili, F.

AU - Vercesi, P.

AU - Arosio, M.

AU - Spada, A.

AU - Peverelli, E.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

AB - Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

KW - Cofilin

KW - Dopamine receptor type 2

KW - Filamin A

KW - Pituitary tumors

KW - Somatostatin receptor 2

UR - http://www.scopus.com/inward/record.url?scp=85059237663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059237663&partnerID=8YFLogxK

U2 - 10.1530/ERC-18-0442

DO - 10.1530/ERC-18-0442

M3 - Review article

C2 - 30589642

AN - SCOPUS:85059237663

VL - 26

SP - R95-R108

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -